TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCAB Considers Discrimination Against Patients, Minority Rates, Smokeless Tobacco April 12, 1985
TCL Archive “A significant reduction in the NCI IRP AIDS program may be in order, and released funds should … increase the pool available to extramural research.” July 21, 1995
